Guide · Updated November 2026

Zepbound vs Mounjaro: Same Drug, Different Price

Zepbound and Mounjaro both contain tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Same molecule, same dose strengths (2.5 to 15 mg). The difference is the FDA label and what you pay. With commercial insurance that covers it, Lilly's savings card can bring Mounjaro to as little as $25. Without insurance, as of Nov 4, 2026, Zepbound through LillyDirect runs $299-$449/month with on-time refills and Mounjaro pens $499/month. Your diagnosis largely determines your price.

The Zepbound vs Mounjaro difference confuses almost everyone I talk to about GLP-1 medications. People assume they are different drugs. They are not. Tirzepatide is tirzepatide. The active ingredient, the manufacturer and the dose strengths are identical. Zepbound also comes in vials and a KwikPen. I have been on Mounjaro for over a year and tracked everything with DEXA scans. If my pharmacy switched me to Zepbound at the same dose tomorrow, nothing about the drug entering my body would change.

What would change is my bill.

That price gap is what this guide is about. I will walk through exactly what each version costs in 2026, who qualifies for the cheapest path, and the specific steps to pay the least for the same medication.

Why the Same Drug Has Two Names (and Two Prices)

Eli Lilly filed two separate FDA applications for tirzepatide. Mounjaro was approved in May 2022 for type 2 diabetes, based on the SURPASS trials measuring A1C reduction. Zepbound was approved in November 2023 for chronic weight management, based on the SURMOUNT trials measuring body weight loss.

The FDA indication on the label drives everything downstream. Insurance formularies, prior authorization rules, copay tiers, and savings programs all flow from whether the drug is classified as a diabetes medication or a weight management medication. In the US healthcare system, those two categories live in completely different worlds.

Diabetes drugs have been on formularies for decades. Insurers expect to cover them. Weight loss drugs are still treated as optional by most plans. That single distinction creates a pricing gap of hundreds of dollars per month for the exact same molecule.

The Real Cost Breakdown (as of Nov 4, 2026)

If you have type 2 diabetes and commercial insurance that covers Mounjaro, the savings card makes it the cheapest way to get tirzepatide. If you are paying out of pocket for weight loss, Zepbound through LillyDirect at $299-$449/month is the cheapest branded option.

For a broader look at all GLP-1 pricing options, including semaglutide, see our complete cost breakdown.

The Clinical Data Is Identical (Because It Is the Same Drug)

I want to be direct about this: there is no clinical reason to prefer one over the other. The SURMOUNT-1 trial (NEJM, July 2022) tested tirzepatide in 2,539 adults with obesity and no diabetes. Results at 72 weeks:

• 5 mg: 15.0% body weight lost
• 10 mg: 19.5% body weight lost
• 15 mg: 20.9% body weight lost
• Placebo: 3.1%

At the highest dose, 57% of participants lost 20% or more of their body weight. Those numbers supported Zepbound’s FDA approval, but the molecule producing those results is the same one in every Mounjaro pen.

The SURMOUNT-5 trial (NEJM, May 2025) compared tirzepatide head-to-head against semaglutide (the molecule in Ozempic and Wegovy). Tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks. That is about 47% more weight loss in relative terms, with fewer GI-related dropouts (2.7% vs 5.6%, per an ACC summary). Whether the pen said Mounjaro or Zepbound, the advantage held.

On body composition: in the SURMOUNT-1 DEXA substudy, tirzepatide reduced fat mass by 33.9% and lean mass by 10.9%, so about 75% of the weight lost was fat and 25% was lean. The same paper cites the STEP 1 semaglutide substudy at about 60% fat and 40% lean. These are separate trials, so treat the lean-to-fat comparison as rough.

Side Effects: Also Identical

Same molecule, same side effects. From the Zepbound label, pooling its two weight-loss trials across the 5, 10 and 15 mg doses:

• Nausea: 25-29% (vs 8% placebo)
• Diarrhea: 19-23% (vs 8%)
• Constipation: 11-17% (vs 5%)
• Vomiting: 8-13% (vs 2%)

Discontinuation due to side effects ranged from 4.8% to 6.7%, vs 3.4% on placebo. The label also carries a boxed warning about thyroid C-cell tumors and warnings including pancreatitis and gallbladder disease, so follow your prescriber’s guidance on dosing. Most side effects hit during dose escalation and fade after a few weeks at each dose. I covered what helped me manage the nausea in our Mounjaro nausea guide, and we have a full GLP-1 side effects timeline if you want the month-by-month picture.

The point: do not pick between Mounjaro and Zepbound based on side effects. They will be identical.

Insurance: The Only Thing That Actually Matters

This is where the Zepbound vs Mounjaro difference becomes real. Not in the drug itself, but in how insurance companies treat it.

If You Have Type 2 Diabetes

Mounjaro is usually the better route. Diabetes drugs are routinely on commercial and Medicare Part D formularies, though your plan may still require prior authorization. With Lilly’s savings card on top of commercial coverage, you may pay as little as $25 for up to a 3-month prescription, subject to the card’s savings caps. Medicare patients cannot use the card.

If You Want Weight Loss Without Diabetes

This is harder. Zepbound is the on-label choice for weight management, but many employer plans still exclude anti-obesity medications entirely. Coverage is growing (some large employers and state programs have added it), but it is far from universal.

If your plan does cover obesity medications, Zepbound works the same way as any covered drug: prior authorization, possible step therapy, then your plan’s copay, which the Zepbound savings card may reduce.

If your plan does not cover it, you have three options:

1. LillyDirect self-pay: $299/month for the 2.5 mg starter dose, $399/month for 5 mg, and $449/month for 7.5 mg and above if you refill within 45 days, otherwise $499 to $699 (vials or KwikPen, checked Nov 4, 2026 on LillyDirect). No insurance needed.
2. Compounded tirzepatide: Not FDA-approved. The FDA declared the tirzepatide shortage over in late 2024 (see below), which ended the shortage-based allowance for mass compounding. See our compounded vs brand-name comparison for the tradeoffs.
3. Ask about Mounjaro: Mounjaro is labeled for type 2 diabetes only. Prescribing it for prediabetes or weight loss is off-label, and most insurers will not cover that. Your diagnosis codes must reflect your real condition.

For step-by-step help figuring out your insurance situation, our GLP-1 insurance coverage guide breaks down the prior authorization process.

Medicare Patients: Limited Options

Medicare Part D covers Mounjaro for type 2 diabetes. Standard Part D still excludes drugs used for weight loss, but it can cover Zepbound for moderate-to-severe obstructive sleep apnea, a separate FDA-approved use.

If you are on Medicare and want tirzepatide for weight loss, check whether you qualify for the Medicare GLP-1 Bridge, which runs July 1, 2026 through December 31, 2027 with a $50 monthly copay for eligible beneficiaries. It covers the Zepbound KwikPen only, not vials or single-dose pens, and requires prior authorization. Otherwise the main path is LillyDirect self-pay ($299-$449/mo with on-time refills), which does not involve insurance. Both are cash-pay paths worth evaluating based on your budget.

The Compounded Third Option

Some telehealth companies still sell compounded tirzepatide. It is not FDA-approved, and the FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed.

The regulatory situation has shifted. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and confirmed that on December 19, 2024. Its enforcement grace periods for copies of the approved drug ended in early 2025 for both 503A pharmacies and 503B outsourcing facilities (March 19, 2025 for 503B). Compounders can no longer routinely make drugs that are essentially copies of Zepbound or Mounjaro. Check our compounded semaglutide legal guide for details, since the same framework applies to tirzepatide.

Of the providers we track, Ro and Hims list brand-name medications only, while MEDVi lists a compounded tirzepatide program. Ask any provider which pharmacy fills the prescription and whether it is licensed in your state.

How to Pay the Least for Tirzepatide in 2026

Here is a decision tree based on your situation:

Step 1: Check your insurance. Do you have commercial insurance? Does it cover Mounjaro (for diabetes) or Zepbound (for weight management)?

Step 2: Talk to your prescriber. If you have type 2 diabetes or prediabetes, Mounjaro with a savings card ($25/mo) is almost certainly your cheapest path. If you do not have diabetes, ask whether your plan covers Zepbound.

Step 3: If insurance says no. Compare LillyDirect Zepbound ($299-$449/mo with on-time refills) vs switching to a semaglutide option that might be cheaper or better covered.

Step 4: Use savings programs. Lilly’s savings cards can stack on top of commercial insurance for Mounjaro or Zepbound, but not on Medicare or Medicaid. The copay card and patient assistance guide has the application links and eligibility details.

For a full pricing comparison across all GLP-1 options (not just tirzepatide), see our cheapest GLP-1 online guide.

Can You Switch Between Mounjaro and Zepbound?

Usually, yes. Your prescriber writes a new prescription for the other brand, typically at the same dose since the drug is identical. Your prescriber makes that call. The pharmacy dispenses whichever one is on the script. The most common reasons to switch:

• Your insurance coverage changes
• One brand has a supply shortage
• You move from a diabetes indication to a weight management indication (or vice versa)
• A different savings program becomes available

One thing to know: pharmacies cannot substitute one for the other on their own. Even though the molecule is identical, they have different NDC codes. Your prescriber needs to write the specific brand.

Bottom Line

Zepbound and Mounjaro are the same drug at different prices. Your diagnosis and insurance determine which one you can access and what you pay. If you have type 2 diabetes and commercial insurance that covers Mounjaro, the savings card (as little as $25) is the best deal in the GLP-1 market. If you are paying cash for weight loss, LillyDirect Zepbound ($299-$449/mo with on-time refills) is the cheapest FDA-approved tirzepatide. Use our provider directory to compare programs that prescribe tirzepatide and find the best fit for your situation.

Frequently Asked Questions

Is there any medical difference between Zepbound and Mounjaro?

No. Both contain tirzepatide made by Eli Lilly in the same dose strengths (2.5 to 15 mg). The only difference is the FDA indication on the label: Mounjaro for type 2 diabetes, Zepbound for weight management. The drug itself is identical.

Why is Mounjaro cheaper than Zepbound for some people?

Insurance coverage. Diabetes medications are routinely covered by commercial plans and Medicare Part D. Weight management drugs face more exclusions. If your commercial insurance covers Mounjaro for diabetes and you use Lilly’s savings card, you may pay as little as $25. Zepbound often requires cash payment through LillyDirect at $299-$449/month.

Can my doctor prescribe Mounjaro for weight loss?

Technically yes, as an off-label prescription, but most insurers will not cover Mounjaro without a type 2 diabetes diagnosis. Zepbound is the on-label weight loss option.

Is compounded tirzepatide the same as Mounjaro and Zepbound?

Compounded tirzepatide is made by compounding pharmacies, not Eli Lilly, and it is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before sale, and the shortage-based allowance for copying the approved drug ended in early 2025.

Can I use my FSA or HSA to pay for Zepbound or Mounjaro?

Prescription drugs used to treat a medical condition, such as diabetes, obesity or sleep apnea, generally qualify under IRS rules. Check with your plan administrator about documentation. See our FSA/HSA guide for details on documentation and reimbursement.

This article is for informational purposes only and does not constitute medical advice. Pricing information is based on publicly available data as of November 4, 2026. Actual costs may vary. Always consult with a qualified healthcare provider before starting any medication.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
• Fat Loss vs Weight Loss · DEXA Scan Results · Mounjaro Plateau · Medicare Coverage · Wegovy Pill vs Injection

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the Zepbound prescribing information, the SURMOUNT-1 and SURMOUNT-5 abstracts, the SURMOUNT-1 body composition paper, LillyDirect pages for Zepbound and Mounjaro, the Mounjaro savings card terms, TrumpRx.gov, Medicare.gov’s GLP-1 Bridge page, and FDA compounding statements on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.